Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Fresenius Kabi Chief Sen Adds Sandoz’ Pawlu

Christian Pawlu Leads Generics And Complex Unit Under New CEO Michael Sen

Executive Summary

As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.

You may also be interested in...



Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash

The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.

Musical Chairs For Off-Patent Executives In 2021

Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.

Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region

Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel